

Cancer Council South Australia

ABN 29 053 873 822

Annual Report - 30 June 2025

Cancer Council South Australia
Contents
30 June 2025

Corporate information	2
Directors' report	3
Auditor's independence declaration	10
Statement of profit or loss and other comprehensive income	11
Statement of financial position	12
Statement of changes in equity	13
Statement of cash flows	14
Notes to the financial statements	15
Directors' declaration	25
Auditor's report	26

Cancer Council South Australia
Corporate information
30 June 2025

Directors	K Maywald DUniv Flin FTSE GICD (Chair) R Batt LL.B. Dip Ed Master of Tech & Comm (int), FAICD (Deputy Chair) N Ashley BSc (Hons), CIPFA, GAICD F Baum AO FASSA, FAAHMS, BA (Hons), PhD B Dodd MBA G Kichenadasse MBBS, FRACP, M Clin Edn, PhD (appointed 26 November 2024) J Russo CIMA®, GDipAppFinInv.B Com(Ec.&Fin.) D Swan BHSmgt, PGDipMExec, GAICD (leave of absence from 20 May 2025) D I Watson, MBBS, MD, PhD, FRACS, FRCSEd (hon), FAHMS (retired 13 November 2024)
Chief Executive	K Rowlands GAICD, CPA, BCom, ADipAcc
Company Secretary	L Ayre BA (Hons), GradDipACG, CPA, FCCA
Auditors	Nexia Edwards Marshall Level 3 153 Flinders Street Adelaide, SA 5000
Bankers	Bank of South Australia 164 Unley Road Unley, SA 5061
Legal	Minter Ellison Lawyers 25 Grenfell St Adelaide, SA 5001
Registered Office	202 Greenhill Road Eastwood. SA 5063
Postal address	PO Box 929 Unley BC, SA 5061

**Cancer Council South Australia
Directors' report
30 June 2025**

The Directors of Cancer Council South Australia (the Company) present their report with respect to the results for the year ended 30 June 2025 together with the Financial Statements of the Company and the Auditor's report thereon.

Cancer Council South Australia's purpose

Our purpose is to reduce the rate and impact of cancer through best practice prevention, research and support.

Our work is focussed on three critical pillars aligned with our purpose: prevention, research and support.

Prevention

We aim to prevent cancer, where possible, through evidence based primary, secondary, and tertiary prevention programs and services.

In Australia approximately 44,000 cancer cases each year (around 1/3 of all cancers diagnosed) are preventable. Cancer Council South Australia is committed to advocating for policy and law changes, at both the state and federal level, where evidence indicates these changes can prevent cancer at both a population and individual level. We will encourage and facilitate access to screening for all South Australians to detect cancers and precancerous conditions, and support people to take action.

Our organisation is dedicated to expanding access to prevention programs and services through placing a greater emphasis on inclusivity and accessibility for all South Australians, including Aboriginal, culturally and linguistically diverse and remote communities.

Research

We value and nurture partnerships that help to maximise South Australia's best and brightest researchers working to minimise the rate and impact of cancer.

Cancer Council South Australia is committed to expanding research to cover cancer prevention, early detection, treatments, survivorship and the wellbeing of people affected by cancer. We aim to increase our focus on translational research to ensure research findings are implemented into clinical policy and practice. We also focus on ensuring community perspectives inform our research priorities.

Our organisation is committed to supporting early and mid-career researchers. By committing to invest in these emerging researchers we are helping to ensure South Australia plays a critical role in developing the next generation of cancer prevention, detection and treatment breakthroughs.

Support

We offer best practice support and information for all South Australians impacted by cancer. Our support services include our 13 11 20 telephone line, staffed by oncology nurses and 120 rooms of supported accommodation in Adelaide for people from regional and remote areas accessing cancer treatment. We are also proud to provide social worker and counselling supports on site.

The aim of our cancer support work is to decrease distress and improve the quality of life of people affected by cancer and assist those close to them. Cancer Council South Australia intends to meet our clients where, when and how they need us. We are committed to expanding the way we deliver our support services to ensure they are easily accessible to everyone, including our Aboriginal, culturally and linguistically diverse and remote communities, as well as people impacted by disabilities. We are committed to continuous improvement of our support services, including evolving how we provide information, counselling and accommodation services to people impacted by cancer to ensure our support meets the community's needs.

Principal activities

The principal activities of Cancer Council South Australia over the past year included:

Cancer Council South Australia
Directors' report
30 June 2025

- empowering South Australians to take steps to reduce their cancer risk through our evidence-based prevention programs, and early detection awareness and education;
- researching new ways to reduce the rate and impact of cancer with support from our research partners;
- supporting all South Australians impacted by cancer with best practice support and information; and
- running fundraising events and campaigns to support the delivery of these programs and services.

Some highlights of our activities in this reporting period include:

- Cancer Council 13 11 20 Nurses made more than 4,500 connections with South Australians for cancer information and support on the phone.
- More than 1,100 counselling sessions were delivered to support individuals through their cancer experience.
- Over 135,000 resources were distributed to the community about cancer prevention, information and support.
- We provided over 35,500 nights of accommodation at our Lodge for regional guests travelling to Adelaide for cancer treatment.
- Transport to Treatment volunteers travelled approximately 32,000 kilometres transporting 42 people per day from Greenhill Lodge to Adelaide medical centres and hospitals.
- We provided 2,499 social worker appointments for our Lodge guests to assist them with emotional and practical support
- The SunSmart Schools and Early Childhood Program protected around 150,000 South Australian children and their educators from harmful UV radiation.
- Cancer Council South Australia awarded over \$1.8million into local, South Australian cancer research.

Review of operations

The operations of Cancer Council South Australia have been carried out to achieve strategic objectives. The operating deficit before recognising the change in the fair value of equity investments is \$(3.26) million (2024: deficit \$(1.68) million). The deficit includes the following:

- \$0.45 million of core mission expenditure specifically approved by the Board as investment of funds from the Restricted Fund Reserve and received in prior years. This expenditure was approved by the Board in accordance with Cancer Council South Australia's Reserves Policy;
- \$1.50 million of investment in the implementation of new cloud-based Software as a Service (SaaS) platforms to enhance operational efficiency, improve data integration, and support secure delivery of services in line with the organisation's strategic objectives. This amount reflects ongoing investment across 2024 and 2025, with the full cost recognised as expenditure in 2025 upon completion of the full implementation of the projects.

Total revenue of \$13.63 million (2024: \$13.76 million) includes \$3.10 million (2024: \$4.61 million) of bequest income.

Although fundraising has been challenging due to a tough economic climate, total fundraising revenue excluding bequests of \$5.80 million was comparable to the previous year's level (2024: \$5.59 million).

Cancer Council South Australia expended \$12.09 million (2024: \$12.06 million) on the core mission activities of cancer research, prevention and support programs throughout the year. Expenditure on prevention and support programs was \$10.26 million (2024: \$8.77 million) with a further \$1.83 million (2024: \$3.29 million) directed to cancer research.

A cash outflow for the year of \$3.7million (2024: \$4.38 million outflow) reflects cash outflow for operating activities and expenditure on a new customer relationship management database which became fully operational in late 2024 and other cloud-based Software as a Service (SaaS) platforms installed during the year.

Likely developments and expected results of operations

Financial assets, being our managed investment portfolio, increased in value by \$4.12 million (2024: \$2.53 million) through the year. This was due to an overall increase in market value of the portfolio and the reinvestment of some income generated from investments. During the year \$1.85 million was drawn down from cash income generated from dividends, interest and unit trust distributions to fund operational expenditure cashflow. This is in line with the investment strategy, which has the objective of investment across several asset classes with the aim of providing more stable income streams and capital growth to better support future operations. We have engaged an external investment manager who has realigned and managed our investment portfolio in accordance with our investment strategy.

Cancer Council South Australia expects fundraising conditions to remain difficult for the coming financial year due to cost-of-living pressures faced by South Australians in the current economic environment. Occupancy levels in our new supportive accommodation facilities increased during the year and are expected to remain at a high level in the coming year.

Cancer Council South Australia
Directors' report
30 June 2025

Cancer Council South Australia continues to maintain a strong net asset position with a high level of liquid and near liquid financial assets, and its financial position remains strong. Cancer Council South Australia does not rely on suppliers to support its operating cash flow through the provisions of extended trading terms.

Cancer Council South Australia notes the unusually high surpluses earned in 2022 and 2023 which are reflected in our Restricted Fund Reserve and General Reserve. Strategies are being implemented to invest these reserves in future initiatives to fulfil our purpose.

Use of reserves

Cancer Council South Australia has included a Restricted Fund Reserve and a General Reserve in the presentation of the Statement of Financial Position. The Restricted Fund Reserve contains bequests and donations that will be applied to the specific purposes for which they were provided. The General Reserve has been created to identify gains made from the sale of capital assets and income which the Board has designed to be 'extraordinary income' (i.e. outside the normal operating budget) this revenue will be applied over time to invest in projects and to build the capacity of the organisation to benefit South Australians affected by cancer, in accordance with our purpose.

In 2025 the total net transfer from these two reserves was \$1.10 million (2024 transfer from reserves of \$0.74 million). The \$1.10 million includes the transfer to the Restricted Fund Reserve of \$0.098m and \$1.198 million transferred from the General Reserve for the investment in building the organisation's digital capacity (\$1.123m) and the Northern Accommodation feasibility study (\$0.075m), all were approved by the Board in accordance with the Reserves Policy .

Significant changes in the state of affairs - change in legal structure

At the Annual General Meeting of Cancer Council South Australia held on 13 November 2024, members of the Anti-Cancer Foundation of South Australia (the Company) resolved to amend the Company's Constitution and change its name to Cancer Council South Australia. The change in name was registered by the Australian Securities and Investments Commission on 28 November 2024.

On 27 February 2025, the Board resolved to further amend the organisation's legal structure, to wind up the Anti-Cancer Foundation of South Australia Trust and settle it on the Company for the Company's sole use and benefit. The resolution provided that the winding up of the Trust would take effect upon completion of the transfer of all Trust assets, employees, and operations to the Company. This transfer was completed on 1 July 2025, with the Trust to be formally wound up following completion of all outstanding reporting requirements for the 2025 financial year.

The decision followed independent legal advice on options available and was undertaken to simplify the organisation's legal structure, clarify governance accountabilities, and improve the efficiency of governance processes. The change has not resulted in any material change to the operations, liabilities, or assets under the control of Cancer Council South Australia.

In the opinion of the Directors, there were no other significant changes in the state of affairs that occurred during the year to 30 June 2025.

Events subsequent to balance date

Other than the change in legal structure coming into force on 1 July 2025, there has not been any matter or circumstance occurring after the end of the financial year that has significantly affected, or may significantly affect, the operations of the company, the results of those operations, or the state of affairs of the company in future financial years.

Members' liability

Cancer Council South Australia is a Company limited by guarantee. Pursuant to the Constitution, each member undertakes to contribute to the property of the Company in the event of it being wound up. The maximum contribution per member in accordance with the guarantee is \$100.

**Cancer Council South Australia
Directors' report
30 June 2025**

Information on directors

The following persons were Directors of Cancer Council South Australia during the twelve-month period and to the date of this report.

The Hon. Karlene Maywald DUnivFlin FTSE GICD
Appointed Director 14 February 2020
Board Chair
Chair, Nomination and Remuneration Committee
Member, Investment Committee

The Hon Karlene Maywald is an experienced Chair and non-executive director across a range of industries in both the private and public sectors including six years as a South Australian State Government Minister and three years as Chair of the National Water Commission.

The Hon Karlene Maywald was elected as the representative for the seat of Chaffey in the South Australian House of Assembly from October 1997 until March 2010. She was appointed as a Minister from 2004 to 2010, holding at times the portfolios of River Murray, Water Security, Regional Development, Small Business, Consumer Affairs, Science/Information Economy, and Minister assisting with Industry and Trade.

She also holds many other Board positions, including Chair of WaterAid Australia, the Adelaide Festival Centre Trust and the CRC for Solving Antimicrobial Resistance in Agribusiness, Food and Environments. She is also a Director of WaterAid International and a Fellow of the Academy of Technical Sciences & Engineering (ATSE).

Mr Nicholas Ashley BSc (Hons), CIPFA, GAICD
Appointed Director 26 October 2023
Chair, Audit, Finance and Risk Committee
Member, Investment Committee

Director Nick Ashley is an experienced senior executive with the Government of South Australia, who has worked in the public sector for over 30 years both here and in the United Kingdom. As a qualified accountant and a graduate of AICD, Nick has a strong accounting and audit background and an in-depth understanding of risk management and governance.

Currently, Nick is the Chief Financial Officer for the South Australian Department of Human Services, which brings together a range of services and policy responsibilities to support communities and individuals. He has also previously held an executive position in the Department of Treasury and Finance.

Nick is passionate about the provision of efficient and effective services to the community, particular to the most vulnerable and disadvantaged residents of South Australia.

Ms Rosey Batt LL.B. Dip Ed Master of Tech & Comm (int), FAICD
Appointed Director 13 May 2021
Deputy Chair, appointed 12 April 2023
Member, Audit, Finance and Risk Committee
Member, Nomination Remuneration and Governance Committee

Rosey Batt is the CEO of Rosey Batt & Associates, a firm providing legal and business services. She is an experienced Non-Executive Director, with her corporate governance expertise strengthened by 30+ years working as a commercial lawyer both locally and internationally, 20+ years facilitating the Australian Institute of Company Directors (AICD) Company Directors' flagship course and her many years of experience as a Non-Executive Director.

In addition to her legal qualifications, Rosey has a Masters in Science & Technology Commercialisation from the University of Texas in Austin and the University of Adelaide. She is a Fellow of the AICD and currently sits on a number of other Boards, including GPEx Limited, the Art Museum of KI Ltd and the Barossa Hills Fleurieu Local Health Network. She is the Chair of the Performance and Risk Committee for the Department of Child Protection and a member of the Central Adelaide Local Health Network (CALHN)'s Audit Committee. She is also a member of the Law Society of SA Ethics and Practice Committee and Litigation Assistance Fund.

Cancer Council South Australia
Directors' report
30 June 2025

Professor Fran Baum AO FASSA, FAAHMS, LMPHAA, BA (Hons), PhD
Appointed Director 16 October 2019
Chair, Cancer Research Committee
Member, Nomination Remuneration and Governance Committee

Professor Fran Baum is a National Health and Medical Research Council Investigator Fellow and Director, Stretton Health Equity at the University of Adelaide. Previously she was a Matthew Flinders Distinguished Professor and Director of the Southgate Institute for Health, Society and Equity at Flinders University. She also served as a Commissioner on the World Health Organisation's Commission on the Social Determinants of Health from 2005-08. Fran was named in the Queen's Birthday 2016 Honours List as an Officer of the Order of Australia (AO) for "distinguished service to higher education as an academic and public health researcher, as an advocate for improved access to community health care, and to professional organisations".

She is a Fellow of the Academy of the Social Sciences in Australia, the Australian Academy of Health and Medical Sciences and of the Australian Health Promotion Association. Fran is a past National President and Life Member of the Public Health Association of Australia. Professor Baum is a member of the British Medical Journal's International Advisory Board. She is a Member of the following Lancet Commission: 1) Gender & Global Health; 2) Political Determinants of Health: Global Governance of Health in Time of Polycrisis; and 3) Tsinghau-Lancet Commission on Health and Poverty Alleviation in China.

Ms Bronwyn Dodd MBA
Appointed Director 31 October 2022
Member, Investment Committee

Bronwyn Dodd is the National General Manager, Indigenous Banking at Westpac. She is a proud Ngarrindjeri woman and accomplished executive with over two decades of leadership experience spanning the banking, government, and health sectors. As National General Manager of Indigenous Banking at Westpac, Bronwyn leads strategic initiatives that promote financial inclusion and drive sustainable economic outcomes for Indigenous communities across Australia.

Her career is distinguished by a commitment to social impact and operational excellence. Prior to joining Westpac, Bronwyn held senior executive roles including Executive Director, Customers and Services at the South Australian Housing Authority, and leadership positions in finance and human resources within both public and private healthcare systems. She has also delivered strong commercial results across SME, Commercial, and Agribusiness markets in the banking sector.

Bronwyn serves as a non-executive director on the boards of Cancer Council South Australia and Indigenous Business Australia's Investment Board, where she contributes her expertise in governance, strategy, and community engagement. Most recently, she was appointed to the inaugural Project Kuiper Global Advisory Board, supporting Amazon's mission to deliver affordable, high-speed broadband to underserved communities worldwide—marking a major milestone with the launch of its first production satellites aboard the Kuiper 1 – ULA Atlas V 551 rocket.

She holds an MBA from the University of Adelaide, completed Australian Institute of Company Directors (AICD) course, and is currently completing a Diploma in Psychology.

Dr Ganessan Kichenadasse MBBS, FRACP, M Clin Edn, PhD
Appointed Director 26 November 2024
Member, Cancer Research Committee

Dr Kichenadasse is an Oncologist and Pharmacologist, currently working at the Department of Medical Oncology at Flinders Medical Centre with special interest in the management of a variety of cancers.

Ganessan is an active member of several national and international cancer and pharmacology professional associations and currently holds a leadership role within the SA Health cancer drug committee.

**Cancer Council South Australia
Directors' report
30 June 2025**

**Mr Jason Russo CIMA®, GDipAppFinInv, B Com(Ec.&Fin.)
Appointed Director 14 October 2020
Chair, Investment Committee**

Jason Russo is a Partner at boutique multi-asset portfolio construction specialists Context Capital. With more than 20 years' experience in multi-asset class portfolio management spanning over Australia and the UK and across private business, public corporations and government organisations, he has led and advised on investment strategies at a managerial, technical and analytical level.

Jason is responsible for client investment strategy and sits on many client investment committees, he is also on the Advisory Board of the University of Adelaide International Centre for Financial Services

**Mr David Swan BHSmtg, PGDipMExec, GAICD
Appointed Director 14 June 2023
Member, Audit, Finance and Risk Committee**

David Swan has more than 25 years' experience as a Chief Executive, leading major public and private sector hospitals, most recently serving as Chief Executive Officer of St. Vincent's Private Hospitals. From 2010-2016, Mr Swan was the Chief Executive of SA Health where he was responsible for South Australia's health system, including covering hospitals, community health, mental health, the ambulance service and research facilities. Mr Swan has been Chair of the Australian Health Ministers' Advisory Council, as well as serving as Chair and Director on numerous private and public boards.

David is currently a Chair of Talent Quarter, and Director of the Board of Northern Adelaide Local Health Network. He is also a member of the Australian Commission on Safety and Quality in Health Care, Executive Chair of Q-bital Healthcare Solutions Pty Ltd, Director of Westfund Health Insurance and interim CEO of Cancer Council Australia.

Directors appointed during the period:

**Dr Ganessan Kichenadasse MBBS, FRACP, M Clin Edn, PhD
Appointed Director 26 November 2024**

Directors retiring during the period:

**Professor David Watson MBBS, MD PhD FRACS, FRACSEd (hon) FAHMS
Appointed Director 14 October 2015, retired 13 November 2024**

Directors' benefits

No Director of Cancer Council South Australia has received or has become entitled to receive a benefit in respect of their role as Directors.

Meetings of directors

The number of Directors' meetings and number of meetings attended by each of the Directors of Cancer Council South Australia during the twelve-month period was:

	Directors' meetings	
	No of Meetings Attended	No of Meetings Eligible to Attend
K Maywald	6	6
N Ashley	5	6
R Batt	5	6
F Baum AO	5	6
B Dodd	3	6
G Kichenadasse	3	3
J Russo	5	6
D Swan	4	5
D Watson	2	2

Cancer Council South Australia
Directors' report
30 June 2025

Director leave of absence

The Board approved a temporary leave of absence effective from 20 May 2025 for David Swan from all Board and Committee activities to manage a conflict of interest that arose due to his appointment on that date as interim CEO of Cancer Council Australia, a member of the Cancer Council federation. This temporary leave of absence will be reviewed upon the conclusion of Mr Swan's appointment as interim CEO of Cancer Council Australia.

Indemnity and insurance of officers

To the extent permitted by law, Cancer Council South Australia has entered into an agreement indemnifying all Directors and Officers against all liabilities to another person, other than Cancer Council South Australia or a related body corporate that may arise from their position as Directors of Cancer Council South Australia or in the capacity of an outside Director for a non-profit outside organisation, except when the liability arises out of conduct involving a lack of good faith.


Cancer Council South Australia has paid insurance premiums in respect of the Association Liability Insurance contract for current and former Directors and Officers.

The contract of insurance prohibits disclosure of the nature of the liability covered and the amount of the premium paid.

Auditor's independence declaration


The auditor's independence declaration is set out on page 10 and forms part of the Directors' report.

This report is made with a resolution of the Directors:



Director

30 October 2025



Director

AUDITOR'S INDEPENDENCE DECLARATION UNDER SUBDIVISION 60-40 OF THE AUSTRALIAN CHARITIES AND NOT-FOR-PROFITS COMMISSION ACT 2012

To the Directors of Cancer Council South Australia

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2025 there have been no contraventions of the auditor independence requirements as set out in any applicable code of professional conduct in relation to the audit.

Nexia Edwards Marshall

Nexia Edwards Marshall
Chartered Accountants



Damien Pozza
Partner

Adelaide
South Australia

30 October 2025

Advisory. Tax. Audit.

Nexia Edwards Marshall (ABN 38 238 591 759) is a firm of Chartered Accountants. It is affiliated with, but independent from Nexia Australia Pty Ltd. Nexia Australia Pty Ltd is a member of Nexia International, a leading, global network of independent accounting and consulting firms. For more information please see www.nexia.com.au/legal. Neither Nexia International nor Nexia Australia Pty Ltd provide services to clients.

Liability limited under a scheme approved under Professional Standards Legislation.

Cancer Council South Australia
Statement of profit or loss and other comprehensive income
For the year ended 30 June 2025

	Note	2025 \$	2024 \$
Revenue from operating activities			
Fundraising	5(i)	8,903,457	10,192,269
Program services			
Supportive accommodation service		2,416,820	2,177,290
Administered program funding	13	1,605,397	791,735
Other income	5(ii)	357,911	266,325
Royalty and licence income	5(iii)	311,708	332,707
Profit on disposal of fixed assets	11	39,409	896
		<u>13,634,702</u>	<u>13,761,222</u>
Expenses from operating activities			
Program services			
Research	6(i)	(1,826,462)	(3,293,900)
Prevention	6(ii)	(4,146,195)	(2,699,529)
Information and support	6(iii)	(6,114,906)	(6,070,263)
Fundraising		(3,536,540)	(3,315,709)
Communication and administration	6(iv)	(4,091,080)	(3,258,266)
		<u>(19,715,183)</u>	<u>(18,637,667)</u>
Result before financial income		<u>(6,080,481)</u>	<u>(4,876,445)</u>
Financial income	7	<u>2,818,988</u>	<u>3,200,112</u>
Operating (deficit)/profit before change in fair value of Equity Investments		<u>(3,261,493)</u>	<u>(1,676,333)</u>
Change in fair value - Equity investments through Profit and Loss		<u>869,414</u>	<u>829,459</u>
Profit / (loss) for the year		<u>(2,392,079)</u>	<u>(846,874)</u>
Other comprehensive income			
<i>Items that will not be reclassified to profit or loss</i>			
Change in fair value - Equity investments through Other Comprehensive Income		<u>1,445,159</u>	<u>932,989</u>
Total comprehensive income / (loss) for the year		<u><u>(946,920)</u></u>	<u><u>86,115</u></u>

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Cancer Council South Australia
Statement of financial position
As at 30 June 2025

	Note	2025 \$	2024 \$
Assets			
Current assets			
Cash and cash equivalents	8	6,877,626	10,576,461
Trade and other receivables	9	2,353,754	2,555,576
Total current assets		<u>9,231,380</u>	<u>13,132,037</u>
Non-current assets			
Other financial assets	10	49,137,406	45,013,640
Property, plant and equipment	11	35,327,219	36,871,339
Total non-current assets		<u>84,464,625</u>	<u>81,884,979</u>
Total assets		<u>93,696,005</u>	<u>95,017,016</u>
Liabilities			
Current liabilities			
Trade and other payables	12	1,401,028	1,920,561
Contract liabilities	13	540,785	484,398
Interest free borrowings		4,000	4,000
Employee benefits	14	788,842	739,962
Total current liabilities		<u>2,734,655</u>	<u>3,148,921</u>
Non-current liabilities			
Employee benefits	14	172,600	132,425
Total non-current liabilities		<u>172,600</u>	<u>132,425</u>
Total liabilities		<u>2,907,255</u>	<u>3,281,346</u>
Net assets		<u>90,788,750</u>	<u>91,735,670</u>
Equity			
FVOCI reserve	15	8,728,203	7,283,044
Restricted fund reserve	15	3,952,998	3,854,268
General reserve	15	40,238,429	41,436,498
Retained earnings		<u>37,869,120</u>	<u>39,161,860</u>
Total equity attributable to equity holder		<u>90,788,750</u>	<u>91,735,670</u>

The above statement of financial position should be read in conjunction with the accompanying notes

Cancer Council South Australia
Statement of changes in equity
For the year ended 30 June 2025

	Reserves \$	Retained Earnings \$	Total Equity \$
Balance at 1 July 2023	52,384,861	39,264,694	91,649,555
Total comprehensive income for the year			
Profit/(Loss) for the year	-	(846,874)	(846,874)
Change in fair value - Equity Investments	932,989	-	932,989
Transfer to/(from) reserves	(744,040)	744,040	-
Total comprehensive income for the year	188,949	(102,834)	86,115
Balance at 30 June 2024	<u>52,573,810</u>	<u>39,161,860</u>	<u>91,735,670</u>
	Reserves \$	Retained Earnings \$	Total Equity \$
Balance at 1 July 2024	52,573,810	39,161,860	91,735,670
Total comprehensive income for the year			
Profit/(Loss) for the year	-	(2,392,079)	(2,392,079)
Change in fair value - Equity Investments	1,445,159	-	1,445,159
Transfer to/(from) reserves	(1,099,339)	1,099,339	-
Total comprehensive income for the year	345,820	(1,292,740)	(946,920)
Balance at 30 June 2025	<u>52,919,630</u>	<u>37,869,120</u>	<u>90,788,750</u>

The above statement of changes in equity should be read in conjunction with the accompanying notes

Cancer Council South Australia
Statement of cash flows
For the year ended 30 June 2025

	Note	2025 \$	2024 \$
Cash flows from operating activities			
Receipts from customers		12,634,109	12,733,254
Payments to suppliers		(17,272,491)	(17,124,662)
Payments for implementation of Software as a Service platforms		(557,956)	(862,171)
Interest received		574,937	719,766
Net cash used in operating activities		(4,621,401)	(4,533,813)
Cash flows from investing activities			
Proceeds from sale of assets		44,383	896
Payments for property, plant and equipment	11	(834,413)	(2,436,595)
Dividends received		2,272,785	2,480,066
Proceeds from sale of investments		12,414,265	5,911,681
Acquisition of investments		(12,974,454)	(5,804,480)
Net cash from investing activities		922,566	151,568
Net cash from financing activities		-	-
Net decrease in cash and cash equivalents		(3,698,835)	(4,382,245)
Cash and cash equivalents at the beginning of the financial year		10,576,461	14,958,706
Cash and cash equivalents at the end of the financial year	8	6,877,626	10,576,461

The above statement of cash flows should be read in conjunction with the accompanying notes

1. Reporting entity

Cancer Council South Australia (the Trustee) is a not-for-profit company limited by guarantee and domiciled in Australia.

The sole object of the Trustee is to act as trustee of the public charitable Trust known as Anti-Cancer Foundation of South Australia (trading as Cancer Council South Australia) and for that purpose the consolidated entity comprises both the Trustee and the Trust. The financial information presented in this financial report are those of the consolidated entity.

In all reports, any reference to the Company is a reference to the consolidated entity. The Trustee does not trade and has no assets and liabilities other than in its capacity as trustee.

2. Basis of preparation

a) Statement of compliance

In the opinion of the Directors, the Company is not publicly accountable. These consolidated financial statements are Tier 2 general purpose consolidated financial report that have been prepared in accordance with Australian Accounting Standards – Simplified Disclosures For-Profit and Not-for-Profit Tier 2 Entities adopted by the Australian Accounting Standards Board (AASB) and the Australian Charities and Not for Profit Commission Act 2012 (ACNC).

This financial report has been approved by the Directors on 30 October 2025.

b) Basis of measurement

The financial statements have been prepared on the historical cost basis except other financial assets which are measured at fair value (see note 3(a)(ii)).

c) Functional and presentation currency

The financial statements are presented in Australian dollars which is the Company's functional currency.

d) Use of estimates and judgements

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenue and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.

e) Basis of consolidation

The Trust is controlled by the Trustee. Control exists when the Trustee has the power, directly or indirectly, to govern the financial and operating policies of an entity so as to obtain benefits from its activities. In assessing control, potential voting rights that presently are exercisable or convertible are taken into account. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases.

Intra-Company balances and transactions, and any unrealised income and expenses arising from intra-Company transactions, are eliminated in preparing the consolidated financial statements.

3. Material accounting policy information

Cancer Council South Australia has consistently applied the following accounting policies to all periods presented in these financial statements.

a) Financial instruments

i. Cash and cash equivalents

Cash and cash equivalents comprise cash balances and call deposits. Cash equivalents are short term, highly liquid investments that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value. The Company invests in term deposits with banks regulated by the Australian Prudential Regulation Authority with maturity dates spread throughout the year.

ii. Financial assets

When financial assets are recognised initially, they are measured at fair value. Financial assets other than those subsequently measured at amortised cost are subsequently measured at fair value. Direct investments in equity securities that are not held for trading are measured at fair value through other comprehensive income. Investments in equity securities through an independently managed unit trust that are not held for trading are measured at fair value through Profit and Loss. Fair value is determined based on fair value (being the redemption value) of all investments.

For direct investments in equity securities that are not held for trading, the Council has elected at initial recognition to present gains and losses in other comprehensive income. For instruments measured at fair value through other comprehensive income, gains and losses are not reclassified to profit or loss and no impairments are recognised in profit or loss. Dividends earned are recognised in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment.

For investments measured at fair value through profit or loss, net gains and losses including interest or dividend income, are recognised in profit or loss.

Financial assets are recognised/de-recognised by Cancer Council South Australia on the date it commits to purchase/sell the investments.

iii. Trade and other receivables

Trade and other receivables are stated at their cost less impairment losses (see accounting policy (f)).

b) Property, plant and equipment

Each class of property, plant and equipment is carried at cost less, where applicable, any accumulated depreciation or impairment write-offs. The carrying amount is reviewed annually to ensure it is not in excess of the remaining service potential of these assets. All classes of property, plant and equipment are depreciated using the straight-line method. The estimated useful lives for the current and comparative periods are as follows:

Buildings	40 years
Motor vehicles	5 years
Plant and equipment	3 - 20 years

c) Software-as-a-Service (SaaS) Arrangements

The Company uses various Software-as-a-Service (SaaS) platforms to support its operations. In line with the IFRS Interpretations Committee decisions (March 2019 and April 2021) and relevant Australian Accounting Standards:

- SaaS arrangements are generally treated as service contracts, not leases (AASB 16) or intangible assets (AASB 138), as the Company does not control the underlying software.
- Subscription fees are expensed over the contract term as services are received.
- Configuration and customisation costs are expensed unless they result in a separate asset that the Company controls. In such cases, costs may be capitalised under AASB 138.
- Prepaid amounts are recognised as assets and expensed over the service period.

This accounting treatment is consistent with AASB 15, AASB 16, AASB 138, and AASB 108 where applicable.

3. Material accounting policy information (continued)

d) Leases

At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Service uses the definition of a lease in AASB 16.

The Company recognises a right-of-use asset and a lease liability at the lease commencement date, unless the lease term ends within 12 months of the acquisition date, or for which the underlying asset is of low value.

The lease liability is measured at amortised cost using the effective interest method. The present value of future lease payments is discounted using the rate implicit in the lease, or if the rate cannot be readily determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate. Under the amortised cost-effective interest method, each period a lease payment is made, the lease liability is partially reduced and interest expense on the lease liability is recognised in the statement of profit or loss and other comprehensive income under 'finance costs'. The interest expense recognised on the lease is relatively higher in the earlier years of the lease than at the end of the lease term.

The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct cost incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset of the site on which it is located, less any incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term, unless the lease term or the cost of the asset reflects that the Company will exercise a purchase option or ownership transfer to the Company at the end of the lease term, in which case the asset is depreciated over the useful life of the asset. Depreciation expense on the right-of-use asset is recognised in the statement of profit or loss and other comprehensive income. In addition, the asset is periodically reduced by impairment losses, if any, and remeasured for certain remeasurements of the lease liability.

e) Assets held for resale

Non-current assets are classified as held-for-resale if it is highly probable that they will be primarily recovered through sale rather than through continuing use. Such assets are measured at the lower of their carrying amount and fair value less costs to sell.

f) Impairment

At each reporting date the carrying amounts of Cancer Council South Australia's tangible and intangible assets are reviewed to determine whether there is any indication of impairment. If any such indication exists the recoverable amount, being the higher of the asset's fair value less costs to sell and value in use, is compared to the asset's carrying value. Any excess of the asset's carrying value over its recoverable amount is expensed to the statement of comprehensive income.

g) Employee benefits

i. Superannuation

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions are recognised when they are due.

3. Material accounting policy information (continued)

ii. Wages, salaries, annual and paid maternity leave

The provisions for employee entitlements to wages, salaries, annual and paid parental leave represent obligations resulting from employees' services provided up to reporting date, calculated at undiscounted amounts based on wage and salary rates, including related on costs, which Cancer Council South Australia expects to pay at each reporting date.

iii. Long-term service benefits

Long term service benefits, plus related on costs, are measured at the present value of future cash outflows. Regardless of the expected timing of settlement, provisions made for annual leave and unconditional long service leave are classified as a current liability where the employee has a present entitlement to the benefit. A non-current liability would include long service leave entitlements accrued for employees with less than 7 years of continuous service.

h) Trade and other payables

Liabilities are recognised for amounts to be paid in the future for goods and services received. The carrying amount of accounts payable approximates fair value.

i) Revenue

i. Charitable support

Revenue is received from community fundraising, legacies and bequests and is brought to account on a cash received basis. When assets, such as investments or properties, are received from a bequest or donation, an asset is recognised at fair value, with a corresponding amount of revenue, when Cancer Council South Australia gains control of such assets.

ii. Interest and dividend revenue

Interest revenue is recognised as it accrues on a daily basis, using the effective interest method. Dividend revenue is recognised in the statement of profit or loss and other comprehensive income on the date the right to receive payments is established, which in the case of quoted securities is normally the ex-dividend date. Where dividends are franked, the dividends are recognised inclusive of imputation credits. Distributions from managed investment funds are recognised as revenue in the period to which they relate.

iii. Sale of goods/services

Revenue from the sale of goods is recognised when control of the goods passes to the customer. Revenue from accommodation facilities is recognised when rooms are occupied and food and beverage is sold.

j) Administered program funding

Operating Grants

Where an agreement is enforceable and contains sufficiently specific performance obligations, the revenue is either recognised over time as the work is performed or recognised at a point in time that the control of the services pass to the customer.

Capital Grants

Where the Company has received assets (including cash) to acquire or construct a non-financial asset, the asset is to be controlled by the Company and there is a refund liability if the terms and conditions of the grant are not met then the asset is recognised as a contract liability on receipt and recorded as revenue as the performance obligation to acquire or construct the asset is completed.

Funds attributable to work still to be completed are recorded as a current liability in the statement of financial position. These funds are invested in fixed interest and at-call facilities in accordance with the grant terms and are included as part of cash and cash equivalents under Note 8.

k) Taxation

i. Goods and services tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (the ATO). In these circumstances the GST is recognised as part of the cost of acquisition or as part of the expense. The net amount of GST recoverable from, or payable to, the ATO is included as a current asset or liability in the Statement of Financial Position.

3. Material accounting policy information (continued)

Cash flows are included in the Statement of Cash Flows on a gross basis. The GST component of cash flows arising from investing and financing activities which are recoverable from, or payable to, the ATO are classified as operating cash flows.

ii. Income tax

Cancer Council South Australia is exempt from income tax under the terms of Section 50(5) of the Income Tax Assessment Act 1997.

l) Fair value reserve

The fair value reserve includes the cumulative net change in the fair value of equity investments.

m) Changes in comparatives

Where necessary, comparative figures have been adjusted to conform to changes in presentation in this financial report.

4. New and amended standards adopted by the Company

There is no material impact on the Company's financial statements from amendments to Australian Accounting Standards that were effective from 1 July 2024.

5. Revenue

Revenue	2025 \$	2024 \$
(i) Fundraising		
Bequests & legacies	3,103,258	4,604,861
Community fundraising	5,800,199	5,587,408
	<u>8,903,457</u>	<u>10,192,269</u>
(ii) Other income		
Other income	357,911	266,325
(iii) Royalty and Licence income	<u>311,708</u>	<u>332,707</u>

6. Program services

Program services	2025 \$	2024 \$
(i) Research		
Research fellowships	383,518	210,306
Beat cancer project	280,000	1,892,000
Internal research programs and strategy support	1,162,944	1,191,594
	<u>1,826,462</u>	<u>3,293,900</u>

The decrease in research expenditure is due to the transition in the year from the Beat Cancer Project to the new Cancer Council SA Research Program, which is being administered inhouse, the decrease reflects the change in timing of payments rather than a decrease in research funding commitments.

(ii) Prevention		
Prevention programs	3,768,266	2,451,819
Tobacco control	377,929	247,710
	<u>4,146,195</u>	<u>2,699,529</u>
(iii) Information and Support Services		
Information and Support programs	1,693,693	1,608,878
Supportive accommodation service	4,421,213	4,461,385

Cancer Council South Australia
Notes to the financial statements
30 June 2025

6. Program services (continued)

	2025	2024
	\$	\$
Program services	<u>6,114,906</u>	<u>6,070,263</u>
(iv) Communication and Administration		
Marketing and Communication	1,245,977	1,456,122
Administration	1,343,337	1,802,144
Software as a Service Platforms (Saas) Cost	1,501,766	-
	<u>4,091,080</u>	<u>3,258,266</u>

Administration Expenses include fees for the audit of the financial report. Audit fees for the year ended 30 June 2025 are \$34,155 (2024: \$33,990).

Communication and Administration expenses include an amount of \$1.5 million relating to the acquisition and implementation of Software-as-a-Service digital platforms, the accounting treatment for these expenses is detailed in Note 3c.

7. Net financial income

	2025	2024
	\$	\$
Interest income	549,169	706,908
Dividends, distributions, and franking credits	<u>2,269,819</u>	<u>2,493,204</u>
	<u><u>2,818,988</u></u>	<u><u>3,200,112</u></u>

8. Cash and cash equivalents

	2025	2024
	\$	\$
Bank balances	1,343,492	1,952,859
Cash held by investment manager for reinvestment	1,334,895	2,569,598
Term deposits maturing within 3 months	4,199,239	6,054,004
Term deposits maturing later than 3 months	-	-
	<u>6,877,626</u>	<u>10,576,461</u>

9. Trade and other receivables

	2025	2024
	\$	\$
Trade receivables at amortised cost	316,556	512,475
Sundry receivables at amortised cost	1,667,694	1,741,409
Prepayments	369,504	301,692
	<u>2,353,754</u>	<u>2,555,576</u>

Cancer Council South Australia
Notes to the financial statements
30 June 2025

10. Other financial assets

	2025 \$	2024 \$
Investments in equity securities	17,715,135	17,111,590
Investments in units in trusts	31,422,271	27,902,050
	<u>49,137,406</u>	<u>45,013,640</u>

11. Property, plant and equipment

	Land \$	Buildings \$	Plant & Equipment \$	Asset under construction \$	Total \$
Cost					
Balance at 1 July 2024	1,250,000	29,920,046	7,302,513	973,121	39,445,680
Acquisitions	-	46,480	581,433	761,757	1,389,670
Transfers	-	229,060	19,480	(248,540)	-
Disposals	-	-	(252,075)	-	(252,075)
Write off of Software as a Service Platforms	-	-	(12,727)	(1,486,338)	(1,499,065)
Balance at 30 June 2025	<u>1,250,000</u>	<u>30,195,586</u>	<u>7,638,624</u>	<u>-</u>	<u>39,084,210</u>
Depreciation and impairment losses					
Balance at 1 July 2024	-	(1,114,210)	(1,460,131)	-	(2,574,341)
Depreciation charge	-	(768,352)	(661,400)	-	(1,429,752)
Disposals	-	-	247,102	-	247,102
Balance at 30 June 2025	<u>-</u>	<u>(1,882,562)</u>	<u>(1,874,429)</u>	<u>-</u>	<u>(3,756,991)</u>
Carrying amounts					
Balance at 1 July 2024	1,250,000	28,805,836	5,842,382	973,121	36,871,339
Balance at 30 June 2025	<u>1,250,000</u>	<u>28,313,024</u>	<u>5,764,195</u>	<u>-</u>	<u>35,327,219</u>

During the financial year, a total of \$0.522 million was invested in enhancements to buildings and car park infrastructure. This included the installation of a generator, balcony reconfiguration, and the introduction of additional security measures.

The motor vehicle fleet replacement was completed at a cost of \$0.185 million, and the ongoing upgrade of computer equipment continued, with an investment of \$0.127 million. In addition, \$0.555 million was spent under the Digital Transformation Plan for the implementation of new Software as Service (SaaS) platforms. This included the rollout of a new Customer Relationship Management (CRM) database, the development of which commenced in the previous year and became operational in September 2024. Asset disposals during the year primarily related to the old motor vehicle fleet and computer and office equipment, which were either fully depreciated or had a negligible net book value at the time of disposal.

During the financial year, management identified that certain software-related costs previously capitalised within *Asset Under Construction* did not meet the recognition criteria for an intangible asset under AASB 138 *Intangible Assets* (refer Note 6(iv)). In accordance with the Company's accounting policy for intangible assets (refer Note 6(iv)), these costs, primarily relating to configuration and customisation services were written off in full during the year.

An amount of \$1.5 million was derecognised from *Asset Under Construction* and expensed to *Software expenses* in the statement of profit or loss for the year ended 30 June 2025.

Cancer Council South Australia
Notes to the financial statements
30 June 2025

12. Trade and other payables

	2025	2024
	\$	\$
Trade payables	616,987	483,004
Other payables	760,118	990,033
Revenue received in advance	-	100,000
Non trade payables and accrued expenses	23,923	347,524
	<u>1,401,028</u>	<u>1,920,561</u>

13. Contract liabilities

	2025	2024
	\$	\$
Funded Projects	<u>540,785</u>	<u>484,398</u>
	2025	2024
	\$	\$
Opening balance	484,398	78,952
Amounts received	1,661,784	1,197,181
Income taken to revenue	(1,605,397)	(791,735)
	<u>540,785</u>	<u>484,398</u>

14. Employee benefits

	2025	2024
	\$	\$
<i>Current liabilities</i>		
Liability for annual leave	440,063	464,615
Liability for long service leave	348,779	275,347
	<u>788,842</u>	<u>739,962</u>
<i>Non-current liabilities</i>		
Liability for long service leave	172,600	132,425
Total employee benefits	<u>961,442</u>	<u>872,387</u>

15. Reserves

	FVOCI	Restricted	General	Total
	reserve	fund reserve	reserve	
	\$	\$	\$	\$
Balance at 1 July 2023	6,350,055	4,598,308	41,436,498	52,384,861
Other comprehensive income	932,989	-	-	932,989
Transfer to/from retained earnings	-	(744,040)	-	(744,040)
Balance at 30 June 2024	<u>7,283,044</u>	<u>3,854,268</u>	<u>41,436,498</u>	<u>52,573,810</u>
Balance at 1 July 2024	7,283,044	3,854,268	41,436,498	52,573,810
Other comprehensive income	1,445,159	-	-	1,445,159
Transfer to/from retained earnings	-	98,730	(1,198,069)	(1,099,339)
Balance at 30 June 2025	<u>8,728,203</u>	<u>3,952,998</u>	<u>40,238,429</u>	<u>52,919,630</u>

15. Reserves (continued)

Financial assets at fair value through other comprehensive income (FVOCI) reserve

The reserve is used to recognise increments and decrements in the fair value of financial assets at fair value through other comprehensive income.

Restricted fund reserve

Donor funds and bequests received for or allocated to specific purposes which have not yet been applied to those purposes.

General reserve

This reserve comprises of extraordinary income as identified by the Board.

16. Key management personnel compensation

The key management personnel compensation was \$1,529,248 for the year ended 30 June 2025 (2024: \$1,491,546). The number of employees defined as key management personnel was 7 (2024: 6) during the financial year.

Included in the number of employees defined as key management personnel are individuals who have joined, resigned, or acted in key management roles during the financial year to cover vacancies and ensure operational continuity. The total number of seven individuals reported as key management personnel reflects this cover, rather than an increase in number of positions which remained constant at six throughout the year.

No directors of Cancer Council South Australia have received or become entitled to receive a benefit in respect of their role as directors.

17. Contractual commitments

As at 30 June 2025, Cancer Council South Australia has contractual commitments in relation to the new Cancer Council South Australia Research Program which is now being administered internally. The funding commitments are with the Adelaide based universities. In conjunction with Flinders University and Flinders Foundation, Cancer Council South Australia is supporting two Research Fellows (Cancer Support and Cancer Wellness) for the final year of a three year program; through the University of South Australia and the University of Adelaide it is supporting eight Research Fellows (Early Career, Mid-Career, National Health and Medical Research Council) for a variety of terms and further funding is committed for a two year period to the University of South Australia for the Peter Nelson Leukemia Fellowship.

In addition, Cancer Council South Australia has committed to the development of a new website, the completion of the implementation of a new finance system, and the licensing of the new Customer Relationship Management database for three years.

Non-cancellable funding agreements and contracts are payable as follows:

	2025	2024
	\$	\$
Not later than that of one year	1,018,346	1,045,542
Later than one year but not later than two years	549,016	275,397
Later than two years but not later than 5 years	467,020	50,000
	<u>2,034,382</u>	<u>1,370,939</u>

18. Events after the reporting period

Until 30 June 2025, Cancer Council South Australia operated as a Charitable Trust controlled by a Corporate Trustee. On 27 February 2025, the Board resolved to wind up the Anti-Cancer Foundation of South Australia Trust and settle it on the Company for the Company's sole use and benefit. The resolution provided that the winding up of the Trust would take effect upon completion of the transfer of all Trust assets, employees, and operations to the Company. This transfer was completed on 1 July 2025, and the Trust will be formally wound up following completion of all outstanding reporting requirements for the 2025 financial year. The change in legal structure has not resulted in any material change to the operations, liabilities, or assets under the control of Cancer Council South Australia.

18. Events after the reporting period (continued)


There have been no other significant changes in the state of affairs of the Company in the period from 30 June to the date of this report that will have a material effect on the Company's financial performance.

Cancer Council South Australia
Directors' declaration
30 June 2025


In the opinion of the Directors of Cancer Council South Australia:

- a) The Company is not publicly accountable.
- b) The financial statements and notes, as set out on pages 15 to 23, are in accordance with Australian Charities and Not-for profits Commission Act 2012, including:
 - i. giving a true and fair view of the financial position of the Cancer Council South Australia as at 30 June 2025 and of its performance, for the financial year ended on that date; and
 - ii. complying with Australian Accounting Standards - Simplified Disclosure Regime and the Australian Charities and Not-for-profits Commission Regulations 2022; and
- c) there are reasonable grounds to believe that the Cancer Council South Australia will be able to pay its debts as and when they become due and payable

Signed in accordance with a resolution of Directors



Director



Director

30 October 2025

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CANCER COUNCIL SOUTH AUSTRALIA

Opinion

We have audited the financial report of Cancer Council South Australia ('the Trustee'), which comprises the statement of financial position as at 30 June 2025, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information, and the directors' declaration.

In our opinion, the accompanying financial report of Cancer Council South Australia, is in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (i) giving a true and fair view of the entity's financial position as at 30 June 2025 and of its financial performance for the year then ended; and
- (ii) complying with Australian Accounting Standards – Simplified Disclosures and Division 60 of the *Australian Charities and Not-for-profits Commission Regulations 2022*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the entity in accordance with the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

The directors are responsible for the other information. The other information comprises the information in Cancer Council's directors' report for the year ended 30 June 2025, but does not include the financial report and the auditor's report thereon.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of the other information we are required to report that fact. We have nothing to report in this regard.

Advisory. Tax. Audit.

Nexia Edwards Marshall (ABN 38 238 591 759) is a firm of Chartered Accountants. It is affiliated with, but independent from Nexia Australia Pty Ltd. Nexia Australia Pty Ltd is a member of Nexia International, a leading, global network of independent accounting and consulting firms. For more information please see www.nexia.com.au/legal. Neither Nexia International nor Nexia Australia Pty Ltd provide services to clients.

Liability limited under a scheme approved under Professional Standards Legislation.

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CANCER COUNCIL SOUTH AUSTRALIA (CONT)

Responsibilities of the Directors for the Financial Report

The directors of Cancer Council South Australia are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards – Simplified Disclosures and the *Australian Charities and Not-for-profits Commission Act 2012* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the entity or to cease operations, or have no realistic alternative but to do so.

The directors are responsible for overseeing the entity's financial reporting process.

Auditor's responsibility for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or taken together, they could reasonably be expected to influence the economic decisions of users taken based on this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by those charged with governance.

Advisory. Tax. Audit.

Nexia Edwards Marshall (ABN 38 238 591 759) is a firm of Chartered Accountants. It is affiliated with, but independent from Nexia Australia Pty Ltd. Nexia Australia Pty Ltd is a member of Nexia International, a leading, global network of independent accounting and consulting firms. For more information please see www.nexia.com.au/legal. Neither Nexia International nor Nexia Australia Pty Ltd provide services to clients.

Liability limited under a scheme approved under Professional Standards Legislation.

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CANCER COUNCIL SOUTH AUSTRALIA (CONT)

Auditor's responsibility for the audit of the financial report (cont)

- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Nexia Edwards Marshall

Nexia Edwards Marshall
Chartered Accountants



Damien Pozza
Partner

Adelaide
South Australia

30 October 2025

Advisory. Tax. Audit.

Nexia Edwards Marshall (ABN 38 238 591 759) is a firm of Chartered Accountants. It is affiliated with, but independent from Nexia Australia Pty Ltd. Nexia Australia Pty Ltd is a member of Nexia International, a leading, global network of independent accounting and consulting firms. For more information please see www.nexia.com.au/legal. Neither Nexia International nor Nexia Australia Pty Ltd provide services to clients.

Liability limited under a scheme approved under Professional Standards Legislation.